Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Histogen Inc.

This article was originally published in Start Up

Executive Summary

Histogen is developing an extracellular matrix aimed at the aesthetics market as well as wound healing and research applications. Its technology derives from fibroblasts isolated from newborns, which are then seeded onto a bead-like structure and provided with growth media, where they secrete extracellular matrix proteins and growth factors. Because the fibroblasts come from newborns, they proliferate more rapidly and can last longer than fibroblasts from adults.
Advertisement

Related Content

Emerging Competitors in the SUI Market
The Rebirth of Dermagraft
Scaffolds in Tissue Engineering
Start-Up Previews (02/2008)
The Rebirth of Dermagraft
Scaffolds in Tissue Engineering
Start-Up Previews (02/2008)

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091534

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel